Invitrocue Email Format
Biotechnology ResearchKentucky, United States11-50 Employees
Invitrocue is a biotechnology research company focusing on 3D cell-based models, including patient-derived organoids from solid cancers. Its Onco-PDO platform supports in vitro drug screening on these organoids to inform personalized cancer treatment decisions. The firm aims to advance faster, more affordable disease therapies and to improve patient care. It is headquartered in Singapore with operations in Australia, China, Hong Kong and Germany, and it lists an address in Kentucky, United States; the company has 11-50 employees. In recent years, Invitrocue has pursued strategic partnerships and mergers, including a 2025 integration with Igenecast and a 2026 merger with Angsanalabs and Pathnova Laboratories, along with a 2026 collaboration with Averywell.